Lupin Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension
Lupin Ltd 路 Press Release 路 28 Sept 2026, 2:41 pm
Lupin Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension Lupin has received tentative approval from the US FDA on 28th Sep'26 for its New Drug Application for Apixaban Oral Suspension (1.25 mg/mL) under the 505(b)(2) pathway. The product represents a novel oral liquid formulation of apixaban鈥攖he active ingredient in Bristol Myers Squibb's Eliquis鈥攄esigned for adult anticoagulation patients facing difficulty swallowing tablets. Upon receipt of final approval, the drug will be manufactured at Lupin's Somerset facility in New Jersey, strengthening the company's differentiated product portfolio and US market presence.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
